論文

査読有り
2018年5月

Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • Akitaka Makiyama
  • ,
  • Kohei Arimizu
  • ,
  • Gen Hirano
  • ,
  • Chinatsu Makiyama
  • ,
  • Yuzo Matsushita
  • ,
  • Tsuyoshi Shirakawa
  • ,
  • Hirofumi Ohmura
  • ,
  • Masato Komoda
  • ,
  • Keita Uchino
  • ,
  • Kyoko Inadomi
  • ,
  • Shuji Arita
  • ,
  • Hiroshi Ariyama
  • ,
  • Hitoshi Kusaba
  • ,
  • Yudai Shinohara
  • ,
  • Miyuki Kuwayama
  • ,
  • Tatsuhiro Kajitani
  • ,
  • Hisanobu Oda
  • ,
  • Taito Esaki
  • ,
  • Koichi Akashi
  • ,
  • Eishi Baba

21
3
開始ページ
464
終了ページ
472
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s10120-017-0759-9

BACKGROUND: Patients with advanced gastric cancer (AGC) are often treated with irinotecan monotherapy as salvage-line therapy. However, the survival benefit of this therapy remains to be elucidated. METHODS: Medical records of AGC patients who were treated with irinotecan monotherapy as salvage-line treatment in six institutions from 2007 to 2014 were reviewed. RESULTS: A total of 146 patients had prior fluoropyrimidine and taxane therapies, and 75.3% had prior platinum therapy. The median age was 66 (range 27-81) years, and 102 males (69.9%) were included. Performance status (PS) was 0/1/2/3 in 53/70/19/4 patients. Eighty-nine patients (61.0%) had two or more metastatic sites. Irinotecan monotherapy as 3rd-/4th-line therapy was performed in 135/11 (92.5%/7.5%). The median number of administrations was 4 (range 1-62). Forty-six patients (31.5%) required initial dose reduction at the physician's discretion. The overall response rate was 6.8%, and the disease control rate was 43.1%. The median PFS was 3.19 months [95% confidence interval (CI) 2.30-4.08 months], and the median OS was 6.61 months (95% CI 5.94-7.28 months). Grade 3/4 adverse events were hematological toxicity (46 patients, 31.5%) and non-hematological toxicity (50 patients, 34.2%). Hospitalization due to adverse events was required in 31 patients (21.2%). Patients with relative dose intensity (RDI) less than 80% showed similar survival to those with RDI 80% or higher. CONCLUSIONS: Irinotecan monotherapy was relatively safely performed as salvage-line treatment for AGC in Japanese clinical practice. Careful patient selection and intensive modification of the dose of irinotecan might possibly be associated with favorable survival.

リンク情報
DOI
https://doi.org/10.1007/s10120-017-0759-9
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28799048
ID情報
  • DOI : 10.1007/s10120-017-0759-9
  • ISSN : 1436-3291
  • PubMed ID : 28799048

エクスポート
BibTeX RIS